Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone acetate + prednisone + LHRH
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
Abiraterone acetate + prednisone + LHRH is a combination regimen used primarily in the treatment of prostate cancer, especially high-risk metastatic castration-sensitive and castration-resistant forms. Abiraterone acetate is a prodrug that inhibits CYP17 (17α-hydroxylase/C17,20-lyase), an enzyme critical for androgen biosynthesis, thereby reducing androgen production from all sources (testes, adrenal glands, and tumor tissue). Prednisone is administered to counteract mineralocorticoid excess caused by abiraterone’s mechanism. LHRH (luteinizing hormone-releasing hormone) agonists or antagonists are included to suppress testicular testosterone production via medical castration. This triple therapy further reduces androgen levels and blocks their action on prostate cancer cells[1][2][3][5][6][7].
- Brand names
- Zytiga
- Other names
- androgen deprivation therapy + abiraterone acetate + prednisone
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GnRHR (Gonadotropin-releasing hormone receptor)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on abiraterone acetate + prednisone + LHRH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone acetate + prednisone + LHRH.